23 June 2023
EMA/PDCO/258156/2023
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 23-26 May 2023

Chair: Brian Aylward – Vice-Chair: Sylvie Benchetrit

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chair opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests concerning the matters for discussion. No new or additional competing interests were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda for 23-26 May 2023 meeting was adopted.

1.3. Adoption of the minutes

The minutes for 24-26 April 2023 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Clindamycin phosphate / adapalene (micronised) / benzoyl peroxide (hydrous) - EMEA-003263-PIP01-22

Bausch Health Ireland Limited; Treatment of acne vulgaris

Day 120 opinion

Dermatology

Summary of Committee discussion:

The PDCO discussed at Day 120, during the May 2023 plenary meeting, the PIP proposal with a waiver for a fixed dose combination (FDC) of clindamycin phosphate, adapalene and benzoyl peroxide in treatment of acne vulgaris. As all studies in the PIP already had been completed at the time of submission there were very limited opportunities to further optimise the plan.
The Committee confirmed all conclusions reached at Day 90 and took into consideration further information provided by the applicant between Day 90 and Day 120.
The PDCO adopted a positive opinion on a paediatric investigation plan with a waiver for children less than 9 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) over existing treatments in the treatment of acne vulgaris.

2.1.2. Spesolimab - EMEA-002475-PIP03-22

Boehringer Ingelheim International GmbH; Treatment of Netherton syndrome

Day 120 opinion

Dermatology

Summary of Committee discussion:

Based on the assessment of this application, additional clarifications received from the applicant, and further discussions at the Paediatric Committee, all issues were considered resolved and a positive opinion was adopted by the PDCO for the PIP for spesolimab for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of Netherton syndrome. The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.3. Sodium 2,2-dimethylbutyrate - EMEA-003019-PIP01-21

Hemoshear Therapeutics Inc.; Treatment of inborn errors of amino acid metabolism

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

In May 2023 the PDCO agreed a positive opinion for a PIP for sodium 2,2-dimethylbutyrate (HST5040) for treatment of inborn errors of amino acid metabolism (treatment of patients with propionic acidaemia (PA) and treatment of patients with methylmalonic acidaemia (MMA)) including one non-clinical study, two clinical studies and a modelling and simulation analysis.

2.1.4. Izokibep - EMEA-003325-PIP01-22

ACELYRIN, INC.; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis, and juvenile idiopathic arthritis)

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for izokibep, for the paediatric population from 2 years to less than 18 years of age in the condition treatment of chronic idiopathic arthritis (including psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis) was adopted.
The PDCO agreed on a waiver in the paediatric population from birth to less than 2 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.
The PDCO granted a deferral for some measures contained in this PIP.

2.1.5. Bictegravir / lenacapavir - EMEA-003324-PIP01-22

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO discussed at Day 120, during the May 2023 plenary meeting, an application for paediatric investigation plan with a waiver and deferral for a fixed dose combination (FDC) of bictegravir / lenacapavir intended for the treatment of HIV infection as a complete dual regimen with once daily administration.
The Committee confirmed all conclusions reached at Day 90 and took into consideration further information provided by the applicant between Day 90 and Day 120.
The PDCO adopted a positive opinion on a paediatric investigation plan with a deferral and a waiver for children less than 2 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients with HIV-1 infection.

2.1.6. Posoleucel - Orphan - EMEA-002908-PIP02-22

AlloVir International DAC; Prevention of viral disease in haematopoietic stem cell transplantation (HCT)

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for all paediatric age subsets, in the condition of prevention of viral disease in haematopoietic stem cell transplantation was adopted.

2.1.7. 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one - Orphan - EMEA-003268-PIP01-22

Bridge Bio Europe B.V.; Treatment of pantothenate kinase-associated neurodegeneration

Day 120 opinion

Other

Summary of Committee discussion:

The PDCO discussed at Day 120, during the May 2023 plenary meeting, an application for a paediatric investigation plan and a waiver, and a deferral for 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671) for treatment of pantothenate kinase-associated neurodegeneration (PKAN).
The Committee confirmed all conclusions reached at Day 90 and took into consideration further information provided by the applicant between Day 90 and Day 120.
The PDCO adopted a positive opinion on a paediatric investigation plan with a deferral and a waiver for children under the age of 6 months of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible in the treatment of pantothenate-associated neurodegeneration.

2.1.8. Immunoglobulin G4 [228-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal REGN5715 γ4-chain), disulphide with human monoclonal REGN5715 κ-chain, dimer / immunoglobulin G4 [227-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal REGN5714 γ4-chain), disulphide with human monoclonal REGN5714 κ-chain, dimer / immunoglobulin G4 [224-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulphide with human monoclonal REGN5713 κ-chain, dimer - EMEA-003270-PIP01-22

Regeneron Ireland DAC; Treatment of allergic rhinitis

Day 120 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the assessment of this application, the additional information provided by the applicant and further discussions at the Paediatric Committee, the PDCO adopted a positive opinion on Day 120 for immunoglobulin G4 [224-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulphide with human monoclonal REGN5713 κ-chain, dimer (REGN5713) / immunoglobulin G4 [227-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal REGN5714 γ4-chain), disulphide with human monoclonal REGN5714 κ-chain, dimer (REGN5714) / immunoglobulin G4 [228-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal REGN5715 γ4-chain), disulphide with human monoclonal REGN5715 κ-chain, dimer (REGN5715) for the treatment of allergic rhinitis in paediatric population from 2 years to less than 18 years of age.
A waiver was granted for the paediatric population from birth to less than 2 years of age on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.
The PDCO granted a deferral for one or more measures contained in this PIP.

2.1.9. ±3,4-methylenedioxymethamphetamine hydrochloride (MDMA) - EMEA-003276-PIP01-22

MAPS Europe B.V.; Treatment of post-traumatic stress disorder

Day 120 opinion

Psychiatry

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion on the PIP in children from 6 years to less than 18 years of age in the condition of 'treatment of post-traumatic stress disorder' was adopted.
The PDCO agreed on a waiver in a subset of children on the grounds that the specific medicinal product is likely to be unsafe. The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.10. Phuket modRNA (PF-07836259) / Darwin modRNA (PF-07871853) / Austria modRNA (PF-07872963) / Wisconsin modRNA (PF-07829855) - EMEA-003318-PIP01-22

Pfizer Europe MA EEIG; Prevention of influenza disease

Day 120 opinion

Vaccines

Summary of Committee discussion:

The PDCO discussed the remaining outstanding points and the responses of the applicant between Day 90 and Day 120. Based on the assessment of this application and further discussions during the PDCO plenary the PDCO agreed on an opinion for a PIP for modRNA encoding 4 influenza HA antigens (2 for influenza A and 2 for influenza B strains) (qIRV) for all subsets of the paediatric population (from 6 weeks to less than 18 years of age) in the condition of prevention of influenza disease. The PIP contains a waiver for the paediatric population from birth to less than 6 weeks of age on the grounds that the specific medicinal product is likely to be ineffective. All studies in the PIP are deferred.

2.1.11. Zapomeran - EMEA-003349-PIP01-22

Arcturus Therapeutics Europe B.V.; Prevention of coronavirus disease 2019 (COVID-19)

Day 90 opinion

Vaccines

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed vaccine for the entire paediatric population in the condition of prevention of coronavirus disease 2019

(COVID-19). The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan. It was also agreed that the first paediatric study should start only when the vaccine composition is adapted to address the dominant circulating SARS-CoV-2 variant(s) or relevant recommendations on the composition of COVID-19 vaccines.

2.1.12. Acetylsalicylic acid / rosuvastatin (calcium) - EMEA-003410-PIP01-23

Swyssi AG; Prevention of cardiovascular events

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application the PDCO agreed with the applicant's request for a waiver.
The PDCO recommended granting a waiver for acetylsalicylic acid / rosuvastatin (calcium) for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'prevention of cardiovascular events' on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.13. Amlodipine (besilate) / rivaroxaban - EMEA-003412-PIP01-23

Teva B.V.; Treatment of hypertension / Prevention of thromboembolic events

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for amlodipine (besilate) / rivaroxaban for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of treatment of hypertension, prevention of thromboembolic events, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.14. Deucravacitinib - EMEA-002350-PIP05-23

Bristol-Myers Squibb Pharma EEIG; Treatment of Sjögren’s syndrome

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for deucravacitinib for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of

Sjögren's syndrome on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical trials are not feasible for all paediatric subsets. The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. Efzofitimod - Orphan - EMEA-003352-PIP02-23

FGK Representative Service GmbH; Treatment of systemic sclerosis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Note: Withdrawal request received on 12 May 2023

2.1.16. Secukinumab - EMEA-000380-PIP11-23

Novartis Europharm Limited; Treatment of rotator cuff tendinopathy

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for the proposed product for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of rotator cuff tendinopathy on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.17. Reparixin - Orphan - EMEA-001693-PIP05-23

Dompé farmaceutici S.p.A.; Treatment of acute respiratory distress syndrome (ARDS)

Day 60 opinion

Infectious Diseases

Note: Withdrawal request received on 11 May 2023

2.1.18. Opicapone - EMEA-003406-PIP01-23

Bial Portela & Ca S.A.; Treatment of Parkinson's disease

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application the PDCO agreed with the applicant's request for a waiver.
The PDCO recommended granting a waiver for opicapone for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of Parkinson's disease' on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.19. Benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-, (4R) - (LY3537982) - EMEA-003409-PIP01-23

Eli Lilly and Company; Treatment of malignant neoplasms of the central nervous system / Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms)

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the May 2023 plenary meeting, a request for a product-specific waiver for benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-, (4R) - (LY3537982) for the treatment of solid malignancies.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 for this product for the treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms) and for the treatment of malignant neoplasms of the central nervous system on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.20. Therapeutic DNA plasmid vaccine targeting HPV16 E6 and E7 proteins (VB10.16) - EMEA-003403-PIP01-23

Nykode Therapeutics ASA; Treatment of human papilloma virus (HPV) type 16 positive malignancies

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the May 2023 plenary meeting, a request for a product-specific waiver for therapeutic DNA plasmid vaccine targeting HPV16 E6 and E7 proteins (VB10.16) for the treatment of cervical cancer and the treatment of head and neck

cancer.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 for therapeutic DNA plasmid vaccine targeting HPV16 E6 and E7 proteins (VB10.16) for the treatment of human papilloma virus (HPV) type 16 positive malignancies.
The applicant agreed for the waiver to be extended to all pharmaceutical forms and all routes of administration.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.21. Fuzuloparib - EMEA-003422-PIP01-23

Luzsana Biotechnology Europe; Treatment of prostate cancer

Day 30 opinion

Oncology

Summary of Committee discussion:

The PDCO discussed at Day 30, during the May 2023 plenary meeting, an application for a waiver for fuzuloparib for treatment of prostate cancer.
Based on the assessment of this application the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for fuzuloparib for all subsets of the paediatric population (from birth to 18 years of age) in the condition of treatment of prostate cancer.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.22. Nizaracianine triflutate - EMEA-003367-PIP01-22

Curadel Surgical Innovations, Inc.; Visualisation of ureter

Day 90 opinion

Diagnostic

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 1 month to less than 18 years of age, in the condition of visualisation of ureter was adopted. The PDCO agreed on a waiver in a subset of children on the grounds of lack of significant therapeutic benefit as clinical studies are not feasible. The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.23. Irinotecan - Orphan - EMEA-003416-PIP01-23

Les Laboratoires Servier; Treatment of pancreatic cancer

Day 30 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for irinotecan for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of pancreatic cancer.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.24. Povidone-iodine - EMEA-003413-PIP01-23

ESPL Regulatory Consulting Limited; Treatment of acute nasopharyngitis (common cold)

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agreed a waiver of its own motion.
The PDCO recommended granting a waiver for povidone-iodine for all subsets of the paediatric population (from birth to less than 18 years of age) for 'treatment of acute nasopharyngitis (common cold)' on the grounds that clinical studies with povidone-iodine might not be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.25. Influenza virus type B, whole virion, inactivated / influenza virus type A H3N2, whole virion, inactivated / influenza virus type A H1N1, whole virion, inactivated - EMEA-003267-PIP02-23

Fluart Innovative Vaccines Kft; Prevention of influenza disease

Day 60 opinion

Summary of Committee discussion:

Based on the assessment of this application, further discussions at the Paediatric Committee, and on the additional information provided by the applicant, the PDCO recommended granting a waiver on its own motion for influenza virus type A H3N2, whole

virion, inactivated / influenza virus type B, whole virion, inactivated / influenza virus type A H1N1, whole virion, inactivated for all subsets of the paediatric population (0 to 18 years of age) in the condition of influenza disease.

2.2. Opinions on Compliance Check

2.2.1. Lenvatinib - EMEA-C-001119-PIP02-12-M08

Eisai GmbH; Treatment of papillary thyroid cancer / Treatment of follicular thyroid cancer / Treatment of osteosarcoma

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO took note of the outcomes of preceding partial compliance check procedures:

- EMEA-C1-001119-PIP02-12
- EMEA-C2-001119-PIP02-12-M01
- EMEA-C3-001119-PIP02-12-M07

The PDCO adopted on 26 May 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0280/2022) of 11 August 2022.

2.2.2. Crisantaspase - EMEA-C-002934-PIP01-20

Jazz Pharmaceuticals Ireland Limited; Treatment of lymphoblastic lymphoma

Day 30 opinion

Oncology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-002934-PIP01-20

The PDCO adopted on 26 May 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0453/2021) of 29 October 2021.
Compliance of Study 3 (completion date) was confirmed.

2.2.3. Baloxavir marboxil - EMEA-C3-002440-PIP01-18-M04

Roche Registration GmbH; Treatment of influenza

Day 60 letter

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed

paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0383/2022 of 9 September 2022).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.2.4. Eladocagene exuparvovec - EMEA-C-002435-PIP01-18-M03

PTC Therapeutics International Limited; Treatment of aromatic L-amino acid decarboxylase deficiency

Day 30 opinion

Neurology

Summary of Committee discussion:

The PDCO discussed at Day 30, during the May 2023 plenary meeting, a request for full compliance check for eladocagene exuparvovec for the treatment of aromatic L-amino acid decarboxylase deficiency.
The PDCO took note of outcomes of the preceding partial compliance check procedure

- EMEA-C1-002435-PIP01-18

and adopted on 26 May 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0075/2023) of 10 March 2023.

2.2.5. Influenza virus surface antigens - A/turkey/Turkey/1/05 (H5N1) - EMEA-C-000599-PIP01-09-M07

Seqirus S.r.l.; Prevention of influenza

Day 30 opinion

Vaccines

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-000599-PIP01-09

The PDCO adopted on 26 May 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0189/2020) of 15 May 2020.

2.3. Opinions on modification of an Agreed Paediatric Investigation Plan

2.3.1. Azilsartan medoxomil - EMEA-000237-PIP01-08-M11

Takeda Development Centre Europe Ltd; Treatment of hypertension

Day 60 opinion

Cardiovascular Diseases

Note: Withdrawal request received on 26 May 2023

2.3.2. Macitentan - Orphan - EMEA-001032-PIP01-10-M06

Janssen-Cilag International NV; Treatment of pulmonary arterial hypertension / Treatment of idiopathic pulmonary fibrosis / Treatment of systemic sclerosis

Day 60 opinion

Cardiovascular Diseases

Note: Withdrawal request received on 24 May 2023

2.3.3. Mavacamten - EMEA-002231-PIP01-17-M01

Bristol-Myers Squibb Pharma EEIG; Treatment of hypertrophic cardiomyopathy

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0106/2019 of 22 March 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Nemolizumab - EMEA-001624-PIP01-14-M06

Galderma International S.A.S; Treatment of atopic dermatitis

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0201/2022 of 21 June 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.5. Rocatinlimab - EMEA-002886-PIP01-20-M03

Amgen Europe B.V; Treatment of atopic dermatitis

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The main changes pertained to some elements in the design of Study 4 (a randomised, double-blind, placebo-controlled, parallel group two part study to investigate the efficacy and safety of rocatinlimab in adolescents aged 12 years to less than 18 years of age with moderate to severe atopic dermatitis).
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0017/2023 of 31 January 2023).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Recombinant parathyroid hormone: rhPTH (1-84) - Orphan - EMEA-001526-PIP01-13-M06

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of hypoparathyroidism

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, and subsequent to internal discussions, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0369/2021 of 8 September 2021). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Potassium chloride / sodium chloride / ascorbic acid / sodium sulfate / sodium ascorbate / polyethylene glycol 3350 - EMEA-001705-PIP02-15-M04

Norgine Limited; Bowel cleansing prior to clinical procedures

Day 60 opinion

Gastroenterology-Hepatology

Note: Withdrawal request received on 16 May 2023

2.3.8. Efgartigimod alfa - Orphan - EMEA-002597-PIP04-21-M01

argenx BV; Treatment of immune thrombocytopenia

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan and the responses submitted after Day 30, the PDCO

considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0078/2022 of 11 March 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.9. Ixekizumab - EMEA-001050-PIP02-18-M02

Eli Lilly and Company (Ireland) Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0280/2019 of 16 August 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Tenofovir alafenamide / emtricitabine / bictegravir - EMEA-001766-PIP01-15-M05

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

In May 2023, while the PDCO was concerned by the delay of the PIP and had differing perspectives regarding proposed conclusion of the clinical study (and interdependent measures) it became evident that accepting the change was the most viable course of action at this time.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0528/2021 of 3 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Soticlestat - Orphan - EMEA-002572-PIP02-19-M03

Takeda Pharma A/S; Treatment of Dravet syndrome / Treatment of Lennox-Gastaut syndrome

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, including the new information received since Day 30, the PDCO considered that only some of the proposed changes could be accepted. At this stage the modification of Study 9 related to PK and PD items was not found sufficiently justified because real PK and PD data are required to confirm/refine the models and to provide dose recommendations.
The PDCO therefore adopted a partially favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0491/2021 of 3 December 2021). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. (4S,7aR,9aR,10S,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,7H-spiro[1,19-ethenocyclobuta[i][1,4]oxazepino[3,4f][1,2,7]thiadiazacyclohexadecine-4,1'-naphthalen]-18(17H)-one 16,16-dioxide (AMG 176) - EMEA-002631-PIP01-19-M02

Amgen Europe BV; Treatment of acute myeloid leukaemia

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0123/2022 of 15 April 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Magrolimab - Orphan - EMEA-002819-PIP01-20-M01

Gilead Sciences International Ltd; Treatment of myelodysplastic syndromes (including juvenile myelomonocytic leukaemia) / Treatment of acute myeloid leukaemia

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0531/2021 of 3 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Talimogene laherparepvec - EMEA-001251-PIP01-11-M06

Amgen Europe B.V.; Treatment of melanoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0005/2022 of 31 January 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.15. Gilteritinib (as fumarate) - Orphan - EMEA-002064-PIP01-16-M05

Astellas Pharma Europe B.V.; Treatment of acute myeloid leukaemia

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0110/2021 of 17 March 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA-002324-PIP01-17-M04

Vertex Pharmaceuticals (Ireland) Limited; Treatment of cystic fibrosis

Day 60 opinion

Other / Pneumology – Allergology

Note: Withdrawal request received on 23 May 2023

2.3.17. Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA-002330-PIP01-18-M03

Pfizer Europe MA EEIG; Prevention of disease caused by *Streptococcus pneumoniae*

Day 60 opinion

Vaccines

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed

paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0239/2022 of 8 July 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Modified vaccinia Ankara - Bavarian Nordic virus (smallpox) - EMEA-001161-PIP02-11-M03

Bavarian Nordic A/S; Prevention of smallpox, mpox and related orthopoxvirus infection

Day 60 opinion

Vaccines

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0539/2022 of 30 December 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.19. NVX-CoV2373 - EMEA-002941-PIP01-20-M03

Novavax CZ, a.s.; Prevention of coronavirus disease 2019 (COVID-19)

Day 60 opinion

Vaccines

Note: Withdrawal request received on 23 May 2023

2.3.20. Recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510) - EMEA-003115-PIP01-21-M01

SK Chemicals GmBH; Prevention of coronavirus disease 2019 (COVID-19)

Day 60 opinion

Vaccines

Note: Withdrawal request received on 23 May 2023

2.3.21. Birch bark extract - Orphan - EMEA-001299-PIP03-17-M02

Amryt Pharmaceuticals DAC; Treatment of epidermolysis bullosa

Day 30 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes concerning the inclusion criteria of the clinical study could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0425/2020 of 22 October 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.22. Cobicistat / darunavir - EMEA-001280-PIP01-12-M06

Janssen-Cilag International NV; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0039/2023 of 31 January 2023). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.23. Givinostat - Orphan - EMEA-000551-PIP04-21-M02

Italfarmaco S.p.A.; Treatment of Duchenne muscular dystrophy

Day 30 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0513/2022 of 4 December 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.4. Opinions on Re-examinations

2.4.1. Tralokinumab - EMEA-001900-PIP02-17-M07

LEO Pharma A/S; Treatment of atopic dermatitis

Final opinion

Dermatology

Summary of Committee discussion:

The Paediatric Committee discussed the re-examination request and considered that the initial opinion should be maintained. This opinion is final, and it supersedes the previous opinion for EMEA-001900-PIP02-17-M07.

2.4.2. Posaconazole - EMEA-000468-PIP02-12-M08

Merck Sharp & Dohme (Europe), Inc.; Prevention of invasive fungal infections / Treatment of invasive fungal infections

Final opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO discussed the re-examination request and found it generally agreeable, with two minor issues requiring further clarification. Upon request the applicant promptly provided the missing information and the PDCO concluded that it was acceptable.
The Paediatric Committee therefore revised its opinion and endorsed the modifications proposed in this re-examination. The revised opinion is final, and it supersedes the previous opinion.

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Selexipag - EMEA-C2-000997-PIP01-10-M06

Janssen-Cilag International NV; Treatment of pulmonary arterial hypertension

Day 30 letter

Other

2.7.2. Evinacumab - EMEA-C2-002298-PIP01-17-M05

Ultragenyx Germany GmbH; Treatment of elevated cholesterol

Day 30 letter

Endocrinology-Gynaecology-Fertility-Metabolism / Cardiovascular Diseases

2.7.3. (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (ALXN2050, vemircopan) - EMEA-C1-002863-PIP01-20

Alexion Europe SAS; Treatment of paroxysmal nocturnal haemoglobinuria

Day 30 letter

Haematology-Hemostaseology

2.7.4. Etranacogene dezaparvovec - EMEA-C1-002722-PIP01-19-M02

CSL Behring GmbH; Treatment of haemophilia B

Day 30 letter

Haematology-Hemostaseology

2.7.5. Delgocitinib - EMEA-C1-002329-PIP02-20-M02

LEO Pharma A/S; Treatment of chronic hand eczema

Day 30 letter

Dermatology

2.7.6. Eliglustat - EMEA-C2-000461-PIP02-11-M05

Genzyme Europe B.V.; Treatment of Gaucher disease type 1 and type 3

Day 30 letter

Other

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Furosemide - EMEA-003316-PIP01-22

Treatment of fluid retention

Day 90 discussion

Cardiovascular Diseases

3.1.2. Milvexian - EMEA-003220-PIP01-22

Prevention of thromboembolism

Day 90 discussion

Cardiovascular Diseases

3.1.3. EMEA-003301-PIP01-22

Treatment of psoriasis

Day 90 discussion

Dermatology

3.1.4. Povorcitinib - EMEA-003313-PIP01-22

Treatment of hidradenitis suppurativa

Day 90 discussion

Dermatology

3.1.5. Ritlecitinib - EMEA-002451-PIP03-22

Treatment of vitiligo

Day 90 discussion

Dermatology

3.1.6. Encaleret - Orphan - EMEA-003348-PIP01-22

Calcilytix Therapeutics, Inc a BridgeBio Company; Treatment of hypoparathyroidism

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.7. Dirloctocogene samoparvovec - Orphan - EMEA-003290-PIP01-22

Spark Therapeutics Ireland Limited; Treatment of haemophilia A

Day 90 discussion

Haematology-Hemostaseology

3.1.8. Mocravimod - Orphan - EMEA-003304-PIP01-22

Priothera SAS; Treatment in haematopoietic stem cell transplantation (HSCT)

Day 90 discussion

Haematology-Hemostaseology

3.1.9. Recombinant human arylsulfatase A - Orphan - EMEA-002050-PIP02-22

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of metachromatic leukodystrophy

Day 90 discussion

Neurology

3.1.10. EMEA-003271-PIP01-22

Treatment of focal onset seizures

Day 90 discussion

Neurology

3.1.11. EMEA-003274-PIP01-22

Treatment of melanoma

Day 90 discussion

Oncology

3.1.12. Dersimelagon - EMEA-002850-PIP03-22

Treatment of systemic sclerosis

Day 90 discussion

Other

3.1.13. mRNA encoding modified human ornithine transcarbamylase - Orphan - EMEA-003315-PIP01-22

Arcturus Therapeutics Europe B.V.; Treatment of ornithine transcarbamylase deficiency

Day 90 discussion

Other

3.1.14. Pamrevlumab - EMEA-002979-PIP04-22

Treatment of interstitial lung diseases with fibrosis

Day 90 discussion

Pneumology - Allergology

3.1.15. Repagermanium - Orphan - EMEA-003154-PIP01-21

Dimerix Bioscience Pty Ltd; Treatment of focal segmental glomerulosclerosis (FSGS)

Day 90 discussion

Uro-nephrology

3.1.16. Influenza recombinant H7 haemagglutinin - EMEA-003314-PIP01-22

Prevention of influenza infection

Day 90 discussion

Vaccines

3.1.17. Single-stranded 5' capped mRNA encoding the HAs of the influenza virus - EMEA-003346-PIP01-22

Prevention of influenza disease

Day 90 discussion

Vaccines

3.1.18. MVA-BN-RSV - EMEA-003185-PIP01-22

Prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV)

Day 90 discussion

Vaccines / Infectious Diseases

3.1.19. Semaglutide - EMEA-003402-PIP01-23

Treatment of non-alcoholic steatohepatitis (NASH)

Day 60 discussion

Gastroenterology-Hepatology

3.1.20. Tetrahydrouridine / decitabine - Orphan - EMEA-003404-PIP01-23

Novo Nordisk A/S; Treatment of sickle cell disease (SCD)

Day 60 discussion

Haematology-Hemostaseology

3.1.21. EMEA-003350-PIP01-23

Prevention of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.22. Belimumab - EMEA-000520-PIP03-23

Treatment of systemic sclerosis

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.23. Daxdilimab - EMEA-003411-PIP01-23

Treatment of systemic lupus erythematosus

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.24. Nipocalimab - Orphan - EMEA-002559-PIP08-23

Janssen-Cilag International NV; Treatment of idiopathic inflammatory myopathies

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.25. Niclosamide ethanolamine - EMEA-003407-PIP01-23

Prevention of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.26. Bidridistrogene xeboparvovec - Orphan - EMEA-003400-PIP01-23

Sarepta Therapeutics Ireland; Treatment of limb-girdle muscular dystrophy type 2E/R4

Day 60 discussion

Neurology

3.1.27. Vemircopan - Orphan - EMEA-002863-PIP02-23

Alexion Europe SAS; Treatment of generalised myasthenia gravis

Day 60 discussion

Neurology

3.1.28. mRNA encoding CMV gB / mRNA encoding the gH protein in the CMV glycoprotein complex pentamer / mRNA encoding the UL131A protein in the CMV glycoprotein complex pentamer / mRNA encoding the UL130 protein in the CMV glycoprotein complex pentamer / mRNA encoding the gL protein in the CMV glycoprotein complex pentamer / mRNA encoding the UL128 protein in the CMV glycoprotein complex pentamer - EMEA-003405-PIP01-23

Prevention of cytomegalovirus infection

Day 60 discussion

Vaccines

3.1.29. Remibrutinib - EMEA-002582-PIP03-23

Treatment of chronic inducible urticaria

Day 30 discussion

Dermatology

3.1.30. Spesolimab - EMEA-002475-PIP04-23

Treatment of hidradenitis suppurativa

Day 30 discussion

Dermatology

3.1.31. EMEA-003414-PIP01-23

Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.32. EMEA-003414-PIP02-23

Treatment of obesity

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.33. Frexalimab - EMEA-002945-PIP03-23

Treatment of type 1 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.34. Mavodelpar - Orphan - EMEA-003331-PIP02-23

Reneo Pharmaceuticals Inc; Treatment of primary mitochondrial disorders

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.35. Modified messenger ribonucleic acid encoding human propionyl-coenzyme a carboxylase alpha and beta subunits encapsulated into lipid nanoparticles - Orphan - EMEA-003419-PIP01-23

Moderna Biotech Spain, S.L.; Treatment of propionic acidaemia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.36. Semaglutide - EMEA-001441-PIP08-23

Reduction in major adverse cardiac events / cardiovascular risk reduction in overweight and obese population

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.37. Semaglutide / cagrilintide - EMEA-003059-PIP02-23

Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.38. Sepiapterin - Orphan - EMEA-003027-PIP02-23

PTC Therapeutics International; Treatment of hyperphenylalaninaemia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.39. Cobitolimod - Orphan - EMEA-001589-PIP02-23

InDex Pharmaceuticals AB; Treatment of ulcerative colitis

Day 30 discussion

Gastroenterology-Hepatology

3.1.40. Autologous CD34+ cells transduced with a lentiviral vector containing a codon-optimised RPS19 gene - Orphan - EMEA-003074-PIP02-23

Apriligen LLC; Treatment of Diamond-Blackfan anaemia

Day 30 discussion

Haematology-Hemostaseology

3.1.41. Rilzabrutinib - Orphan - EMEA-002438-PIP04-23

Sanofi B.V.; Treatment of warm autoimmune haemolytic anaemia

Day 30 discussion

Haematology-Hemostaseology

3.1.42. Belumosudil - Orphan - EMEA-003425-PIP01-23

Sanofi Winthrop Industrie; Treatment of transplant complications

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.43. Trimodulin (human IgM, IgA, IgG solution) - EMEA-002883-PIP03-23

Treatment of lower respiratory tract and lung infections

Day 30 discussion

Neonatology - Paediatric Intensive Care / Infectious Diseases / Pneumology - Allergology

3.1.44. Sotuletinib - Orphan - EMEA-003415-PIP01-23

Novartis Europharm Limited; Treatment of amyotrophic lateral sclerosis (ALS)

Day 30 discussion

Neurology

3.1.45. Abemaciclib - EMEA-002342-PIP04-23

Treatment of neuroblastoma

Day 30 discussion

Oncology

3.1.46. Atezolizumab / tiragolumab - EMEA-003418-PIP01-23

Treatment of lung carcinoma (non-small cell carcinoma)

Day 30 discussion

Oncology

3.1.47. Autologous dendritic cells pulsed with allogeneic tumour cell lysate - Orphan - EMEA-002381-PIP02-23

Amphera BV; Treatment of pancreatic cancer

Day 30 discussion

Oncology

3.1.48. Blinatumomab - Orphan - EMEA-000574-PIP03-23

Amgen Europe B.V.; Treatment of acute lymphoblastic leukaemia

Day 30 discussion

Oncology

3.1.49. Domvanalimab - EMEA-003429-PIP01-23

Treatment of lung cancer

Day 30 discussion

Oncology

3.1.50. Domvanalimab - EMEA-003429-PIP02-23

Treatment of gastric, gastroesophageal junction and oesophageal adenocarcinoma

Day 30 discussion

Oncology

3.1.51. Olutasidenib - Orphan - EMEA-003421-PIP01-23

Rigel Pharmaceuticals B.V.; Treatment of acute myeloid leukaemia

Day 30 discussion

Oncology

3.1.52. Tazemetostat - Orphan - EMEA-003055-PIP02-23

Ipsen Pharma; Treatment of follicular lymphoma

Day 30 discussion

Oncology

3.1.53. Volrustomig - EMEA-003423-PIP01-23

Treatment of lung cancer (small cell and non-small cell lung cancer) / Treatment of renal cell cancer / Treatment of cervical cancer / Treatment of malignant pleural mesothelioma

Day 30 discussion

Oncology

3.1.54. Zimberelimab - EMEA-003427-PIP01-23

Treatment of lung cancer

Day 30 discussion

Oncology

3.1.55. Zimberelimab - EMEA-003427-PIP02-23

Treatment of gastric, gastroesophageal junction, and oesophageal adenocarcinoma

Day 30 discussion

Oncology

3.1.56. Cedazuridine / decitabine - Orphan - EMEA-003071-PIP02-23

Otsuka Pharmaceutical Netherlands B.V.; Treatment of myelodysplastic syndromes

Day 30 discussion

Oncology / Haematology-Hemostaseology

3.1.57. Satralizumab - Orphan - EMEA-001625-PIP05-23

Roche Registration GmbH; Treatment of thyroid eye disease (TED)

Day 30 discussion

Ophthalmology / Neurology

3.1.58. Iptacopan - EMEA-002705-PIP05-23

Treatment of immune-complex mediated membranoproliferative glomerulonephritis (IC-MPGN)

Day 30 discussion

Other

3.1.59. Autologous cell product composed of CD34+ enriched haematopoietic stem cells (HSCs) that have been genetically modified to express the functional β-glucocerebrosidase (GCase) protein - Orphan - EMEA-003424-PIP01-23

AVROBIO, Inc.; Treatment of Gaucher disease type 1 / Treatment of Gaucher disease type 2 / Treatment of Gaucher disease type 3

Day 30 discussion

Other / Pain / Endocrinology-Gynaecology-Fertility-Metabolism / Pneumology - Allergology / Gastroenterology-Hepatology / Haematology-Hemostaseology / Neurology

3.1.60. Sodium lactate / xylitol / magnesium chloride hexahydrate / calcium chloride dihydrate / sodium chloride / L-carnitine / D-glucose - EMEA-003417-PIP01-23

Treatment of patients in need of peritoneal dialysis

Day 30 discussion

Uro-nephrology

3.1.61. mRNA encoding for the linked NTD and RBD domains of the spike glycoprotein of SARS-CoV-2 - EMEA-003426-PIP01-23

Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines / Infectious Diseases

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Clascoterone - EMEA-C-003330-PIP01-22

Cassiopea S.p.A; Treatment of acne vulgaris

Day 30 discussion

Dermatology

3.2.2. Marstacimab - EMEA-C1-002285-PIP02-19-M02

Pfizer Europe MA EEIG; Treatment of congenital haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.2.3. Rilpivirine (hydrochloride) - EMEA-C-000317-PIP01-08-M13

Janssen-Cilag International NV; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.2.4. Teriflunomide - EMEA-C-001094-PIP01-10-M04

Sanofi Aventis Groupe; Treatment of multiple sclerosis

Day 30 discussion

Neurology

3.2.5. Imetelstat - EMEA-C1-001910-PIP03-20-M01

Geron Corporation; Treatment of myelodysplastic syndromes (MDS), including juvenile myelomonocytic leukaemia (JMML)

Day 30 discussion

Oncology

3.2.6. Peanut (*Arachis hypogaea*) allergen powder (previously known as peanut flour) - EMEA-C-001734-PIP01-14-M06

Aimmune Therapeutics Ireland Ltd; Treatment of peanut allergy

Day 30 discussion

Pneumology - Allergology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Beremagene geperpavec - Orphan - EMEA-002472-PIP03-22-M01

Krystal Biotech, Inc.; Treatment of dystrophic epidermolysis bullosa

Day 30 discussion

Dermatology

3.3.2. Dupilumab - EMEA-001501-PIP07-20-M01

Sanofi Winthrop Industrie; Treatment of chronic spontaneous urticaria

Day 30 discussion

Dermatology

3.3.3. Inclisiran - EMEA-002214-PIP01-17-M02

Novartis Europharm Ltd.; Treatment of elevated cholesterol

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.4. Obeticholic acid - Orphan - EMEA-001304-PIP02-13-M07

Advanz Pharma Limited; Treatment of primary biliary cholangitis (PBC)

Day 30 discussion

Gastroenterology-Hepatology

3.3.5. PF-06865571 - EMEA-002773-PIP01-20-M01

Pfizer Europe MA EEIG; Treatment of non-alcoholic steatohepatitis (NASH)

Day 30 discussion

Gastroenterology-Hepatology

3.3.6. Iron as ferric maltol - EMEA-001195-PIP01-11-M06

Norgine BV; Treatment of iron deficiency anaemia (IDA)

Day 30 discussion

Haematology-Hemostaseology

3.3.7. Ibrutinib - EMEA-001397-PIP04-17-M02

Janssen-Cilag International NV; Treatment of chronic graft-versus-host disease

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.8. Tofacitinib citrate - EMEA-000576-PIP01-09-M15

Pfizer Europe MA EEIG; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.9. Delandistrogene moxeparvovec - Orphan - EMEA-002677-PIP01-19-M03

Roche Registration GmbH; Treatment of Duchenne muscular dystrophy

Day 30 discussion

Neurology

3.3.10. Erenumab - EMEA-001664-PIP02-15-M06

Novartis Europharm Limited; Prevention of migraine headaches

Day 30 discussion

Neurology

3.3.11. Lacosamide - EMEA-000402-PIP03-17-M07

UCB Pharma S.A.; Treatment of generalised epilepsy and epilepsy syndromes

Day 30 discussion

Neurology

3.3.12. Abemaciclib - EMEA-002342-PIP01-18-M03

Eli Lilly and Company Limited; Treatment of Ewing's sarcoma

Day 30 discussion

Oncology

3.3.13. Abemaciclib - EMEA-002342-PIP02-18-M02

Eli Lilly and Company Limited; Treatment of glioma / Treatment of neuroblastoma

Day 30 discussion

Oncology

3.3.14. Avapritinib - Orphan - EMEA-002358-PIP02-18-M03

Blueprint Medicines (Netherlands) B.V.; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

Day 30 discussion

Oncology

3.3.15. Cabozantinib - Orphan - EMEA-001143-PIP01-11-M06

Ipsen Pharma; Treatment of malignant solid tumours

Day 30 discussion

Oncology

3.3.16. Olaparib - EMEA-002269-PIP01-17-M02

AstraZeneca AB; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)

Day 30 discussion

Oncology

3.3.17. Quizartinib - Orphan - EMEA-001821-PIP01-15-M07

Daiichi Sankyo Europe GmbH; Treatment of acute myeloid leukaemia

Day 30 discussion

Oncology

3.3.18. Bupropion (hydrochloride) / naltrexone (hydrochloride) - EMEA-001373-PIP01-12-M05

Orexigen Therapeutics Ireland Limited; Treatment of obesity

Day 30 discussion

Other

3.3.19. Tirzepatide - EMEA-002360-PIP02-22-M01

Eli Lilly and Company; Treatment of obesity

Day 30 discussion

Other

3.3.20. Ketamine / sufentanil - EMEA-001739-PIP02-16-M02

Cessatech A/S; Treatment of acute pain

Day 30 discussion

Pain

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of submissions of applications with start of procedure 22 May 2023 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

No item

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

No item

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

6.1.1. Bepranemab - EMEA-02-2023

UCB Pharma S.A.; All classes of medicinal products for treatment of Alzheimer's disease / Treatment of Alzheimer's disease

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's decision CW/0001/2015 to the planned therapeutic indication was confirmed.
Other potential paediatric interests of this medicine suggested by PDCO: none identified at this stage.

6.1.2. Ixoberogene soroparvovec - EMEA-03-2023

Adverum Biotechnologies, Inc.; All classes of medicinal products for treatment of age-related macular degeneration and diabetic macular oedema / Treatment of neovascular

(wet) age-related macular degeneration in adult patients

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's decision CW/0001/2015 to the planned therapeutic indication was confirmed.
Other potential paediatric interests of this medicine suggested by PDCO: retinopathy of prematurity.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Ziltivekimab - EMEA-002840-PIP01-20

Novo Nordisk A/S; Prevention of cardiovascular events in patients with atherosclerosis

Proposed indication: Prevention of major adverse cardiovascular events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with acute myocardial infarction'

Summary of Committee discussion:

The PDCO considered that the proposed indication of 'prevention of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with acute myocardial infarction' is not covered by the agreed PIP condition of 'prevention of cardiovascular events in patients with atherosclerosis' as the proposed indication is broader than the PIP condition. The applicant should include in the wording of the indication specification of acute myocardial infarction type I and/or caused by atherosclerosis.

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO membership

No item

9.1.2. Vote by Proxy

None

9.1.3. Strategic Review and Learning Meeting (SRLM) - Uppsala, 7-8 June 2023

Summary of Committee discussion:

The agenda of the next strategic review and learning meeting in Uppsala was shared with PDCO members.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

The list of PIP-related CHMP procedures starting in April 2023, was presented to the PDCO members.

Feedback on the ongoing CHMP procedures was provided to the Committee by the nominated PDCO experts.

An overview of discussions on PIP-related procedures, held by the CHMP in May 2023, was provided by a CHMP / PDCO member.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Party: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The Vice-Chair of the Non-clinical Working Party (NcWP) identified the products which will require NcWP evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward (*ad interim*)

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.3.3. Patients and Consumers Working Party (PCWP)/Healthcare Professionals Working Party (HCPWP)

Summary of Committee discussion:

The Agenda - HCPWP plenary meeting - 27 June 2023, Agenda – PCWP and HCPWP joint meeting – 28 June 2023, Agenda – PCWP plenary meeting – 27 June 2023, Meeting Summary PCWP HCPWP meeting - 3 March 2023 were presented for information.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

No item

9.5. Cooperation with International Regulators

9.5.1. Paediatric Cluster Teleconference

Summary of Committee discussion:

The May 2023 agenda of the cluster was shared with the PDCO members for information.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

No item

9.8. Planning and reporting

9.8.1. EMA Business Pipeline activity and Horizon scanning

No item

9.8.2. Marketing Authorisation Applications (MAAs) 3-year forecast report (March 2023 to December 2025)

Summary of Committee discussion:

PDCO was presented with the 2023-2025 MAAs forecast report. The pipeline of products up to December 2025 was briefly highlighted. The Committee suggested for the next edition of the report to highlight applications relevant for the paediatric population.

10. Any other business

10.1. COVID-19 Update

Summary of Committee discussion:

The COVID-19 update has been cancelled.

10.2. Feedback on the discussion during the internal operations BOS on the External Data Safety Monitoring Board (eDSMBs)

PDCO member: Siri Wang

Summary of Committee discussion:

The Committee was informed about the discussion on the requirements for eDSMBs in the PIP. PDCO generally agreed to the main conclusions of this discussion (eDSMB as a default unless justified otherwise based on the corresponding guideline and the Q&A document). Further discussion with CTCG is needed (alignment/criteria), as well as input from clinicians / EnprEMA.

10.3. Guideline on allergen products development in moderate to low-sized study populations

Summary of Committee discussion:

The draft guideline on allergen products development in moderate to low sized study populations was presented to the PDCO. It was mentioned that for allergen immunotherapy (AIT) products there exists a standard PIP which will not be feasible for products within the scope of the guideline. PDCO members were therefore asked to comment on how to deal with the requirement of a PIP for both AIT and diagnostic products.

10.4. Report on experience with RWE studies to support EMA scientific committees

Summary of Committee discussion:

EMA presented a report of the experience gained so far with the conduct of RWD studies to support regulatory decisions. The main learnings and recommendations were presented and comments on the report invited within a 2-weeks period.

10.5. Request for feedback of requirements for development in children related to the revision of the orally inhaled products (OIP) guideline

Summary of Committee discussion:

The Chair of the OIP DG presented two questions which PDCO was asked about related to the need for additional studies in children and addressed the question raised by the Committee. Following the plenary discussion, it was agreed that the Committee would provide a consolidated answer by 9 June 2023.

10.6. Workshop on ICH E6 (R3) in July 2023

Summary of Committee discussion:

ACT EU PA04 coordinator presented the upcoming multi-stakeholder workshop on ICH E6(R3) – Public Consultation, which takes place on 13-14 July 2023. This Workshop aims to promote the public consultation and engage relevant stakeholders of ICH E6(R3). Registration closes on 16 June 2023.

10.7. Upcoming Innovation Task Force (ITF) meetings

Summary of Committee discussion:

The presentation on the upcoming ITF briefing meeting has been shared with the PDCO.

11. Breakout sessions

11.1. Paediatric oncology

Summary of Committee discussion:

The group discussed issues of currently assessed PIPs and was informed of upcoming meetings related to paediatric oncology.

11.2. Neonatology

Summary of Committee discussion:

The group discussed organisational aspects for the review of the neonatal guideline.

11.3. Internal PDCO Operations

Summary of Committee discussion:

The PDCO discussed the need for including the requirement of eDSMBs in PIP opinions which is relevant for most studies including the paediatric population.

11.4. Vaccines

Summary of Committee discussion:

Members discussed relevant procedures in preparation for plenary discussion.

11.5. HIV

Summary of Committee discussion:

Members discussed relevant procedures in preparation for plenary discussion.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 23-26 May 2023 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Brian Aylward	Chair	Ireland	No interests declared	
Johanna Wernsperger	Alternate	Austria	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussion, final deliberations and voting on: No participation in final deliberations and voting on:	2.4.2. Posaconazole - EMEA-000468-PIP02-12-M08 3.3.8. Ibrutinib - EMEA-001397-PIP04-17-M02
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Louisa Braun Exner	Alternate	Denmark	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member (Vice-Chair)	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Adrienn Horváth	Member	Hungary	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Cinzia Ciceroni	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Carola de Beaufort	Member	Luxembourg	No restrictions applicable to this meeting	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Olivier Moes	Alternate	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No restrictions applicable to this meeting	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Sara Vennberg	Member	Sweden	No interests declared	
David Khan	Alternate	Sweden	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jose Ignacio Malagon Calle	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Tomasz Grybek	Member	Patients' Organisation	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
		Representative		
Celine Chu	Expert - via telephone*	France	No interests declared	
María Estela Moreno Martín	Expert - via telephone*	Spain	No interests declared	
Andreas Bonertz	Expert - via telephone*	Germany	No interests declared	
Susanne Kaul	Expert - via telephone*	Germany	No interests declared	
Jose Manuel Zubeldia	Expert - via telephone*	Spain	No interests declared	
Diana Hartenstein	Expert - via telephone*	Germany	No interests declared	
Karolina Torneke	Expert - via telephone*	Sweden	No interests declared	
Olga Kholmanskikh	Expert - via telephone*	Belgium	No interests declared	
Meeting run with support from relevant EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (*section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs*)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (*section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check*)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (*section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP*)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (*section 6 Discussion on the applicability of class waiver*)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (*section 8*)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/